TG Therapeutics 경영진
경영진 기준 점검 2/4
TG Therapeutics CEO는 Mike Weiss, Dec2011 에 임명되었습니다 의 임기는 14.58 년입니다. 총 연간 보상은 $25.57M, 3.4% 급여 및 96.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $269.33M 가치에 해당하는 회사 주식의 3.46% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 14.6 년과 12.6 년입니다.
핵심 정보
Mike Weiss
최고경영자
US$25.6m
총 보수
| CEO 급여 비율 | 3.42% |
| CEO 재임 기간 | 14.6yrs |
| CEO 지분 보유율 | 3.5% |
| 경영진 평균 재임 기간 | 14.6yrs |
| 이사회 평균 재임 기간 | 12.6yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jun 22
TGTX: Fair Outlook As Late Stage Multiple Sclerosis Data Supports Recovery
Analysts have raised their price target for TG Therapeutics to $51.71 from $44.43, citing updated assumptions around profit margins, discount rate and future P/E that support a higher fair value estimate. What’s in the News for TG Therapeutics TG Therapeutics reported positive Phase 3 ENHANCE trial results showing a single 600 mg Day 1 infusion of BRIUMVI provided bioequivalent exposure to the existing two-step regimen, with safety and MRI outcomes consistent with prior studies, and plans a supplemental BLA filing in the second half of 2026.분석 기사 • Jun 17
TG Therapeutics (TGTX) Stock Looks 14% Overvalued as BRIUMVI Launch Hopes Face Off With Momentum
Recent Performance Snapshot for TG Therapeutics Stock TG Therapeutics (TGTX) has drawn fresh attention after a stretch of strong share price performance, with the stock up 0.5% in the latest session and gaining over the past week, month and past 3 months. At a last close of $50.54, TG Therapeutics now carries a market value of about $7.1 billion, supported by reported revenue of $700.349 million and net income of $461.896 million from its commercial stage biopharmaceutical operations. See our...
내러티브 업데이트 • Jun 05
TGTX: Expanded Autoimmune Pipeline Will Support A Future Earnings Re Rating
Analysts have raised their fair value estimate for TG Therapeutics by $10 to $70, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels reflected in recent Street research. What's in the News TG Therapeutics reported Q1 2026 total global revenue of about US$205 million, with U.S. BRIUMVI net product revenue of roughly US$195 million and earnings per share of US$0.12 to US$0.17 versus Street expectations of US$0.28 to US$0.30.
내러티브 업데이트 • May 21
TGTX: Execution Risks And Lower P/E Assumptions Will Pressure Future Upside
Narrative Update on TG Therapeutics The updated analyst price target for TG Therapeutics moves slightly lower to about $17.46 from roughly $17.57 as analysts adjust their assumptions on revenue growth, profit margins and future P/E, while still reflecting recent Street research that includes a $10 upward revision from H.C. Wainwright. Analyst Commentary Behind the modest adjustment in the average price target to about $17.46, bearish analysts remain focused on execution risks and how those could affect the valuation that investors are willing to pay for TG Therapeutics.내러티브 업데이트 • Apr 29
TGTX: JPMorgan Cut And Execution Risks Will Pressure Future Upside Potential
Analysts have modestly raised their fair value estimate for TG Therapeutics to about $17.57 per share, from roughly $17.32, citing refreshed assumptions around revenue growth, profit margins, discount rates and future P/E, as well as recent Street research including the latest JPMorgan price target update. Analyst Commentary Recent Street research, including a reduced price target at JPMorgan, points to a more cautious tone around TG Therapeutics, even as fair value estimates move only slightly.Seeking Alpha • Apr 19
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
Summary TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version’s trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets. TGTX enhances financial flexibility with a $750 million term loan, expanded buybacks, and no equity dilution, supporting ongoing growth initiatives. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 15
TGTX: Recent JPMorgan Cut Will Likely Expose Fragile Earnings Expectations
Analysts have adjusted their fair value estimate for TG Therapeutics from $15.49 to $17.32, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent price target revisions, including the $3 cut highlighted by JPMorgan. Analyst Commentary Recent commentary around TG Therapeutics has tilted cautious, with the $3 price target cut at JPMorgan reinforcing a more conservative stance on both execution and valuation risk.내러티브 업데이트 • Mar 31
TGTX: Shares Should Advance As Durable Multiple Sclerosis Data Supports Recovery
Narrative Update The blended analyst price target for TG Therapeutics is now effectively unchanged around $44, as recent moves, including a $3 trim at one firm and modest raises at others, reflect updated views on sector funding conditions, deal activity, and regulatory risk, while leaving core assumptions on growth, margins, and future P/E largely intact. Analyst Commentary Recent Street research around TG Therapeutics has been active but mixed, with one major firm trimming its target while others lift theirs, leaving the blended target roughly unchanged.내러티브 업데이트 • Mar 17
TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Drives Confidence
Analysts recently adjusted their price targets for TG Therapeutics in a mixed way, with one firm cutting its target by $3 while others raised theirs by $2 and $2. These changes reflect updated views on sector conditions, access to capital, M&A activity and company specific data catalysts.내러티브 업데이트 • Mar 03
TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Supports Upside
Analysts have nudged their price targets on TG Therapeutics in both directions recently, with moves such as a $3 trim at one firm and a $2 lift at another. These changes reflect updated views on discount rates, revenue growth assumptions, profit margins and future P/E, rather than a wholesale shift in the $44.43 fair value estimate used in this model.내러티브 업데이트 • Feb 17
TGTX: Shares Should Rebound As Revenue Outlook Supports Mixed Street Views
Analysts have made only a modest adjustment to their TG Therapeutics price targets, reflecting a slightly higher assumed discount rate and marginally lower future P/E expectations, while maintaining a consistent fair value estimate near $44 per share. Analyst Commentary Recent Street research on TG Therapeutics has been mixed, with some firms lifting price targets and others trimming them.내러티브 업데이트 • Feb 02
TGTX: Shares Should Rebound As Mixed Street Views Contrast With Strong Revenue Outlook
Analysts have adjusted their blended price target on TG Therapeutics slightly lower, trimming fair value by about $0.43 to reflect updated assumptions around growth, margins and future P/E following a mix of recent target revisions from major firms. Analyst Commentary Recent Street research on TG Therapeutics reflects a mix of optimism on the setup for biotech and specific caution around the company’s execution and valuation, which is feeding into the modest trim in the blended price target.내러티브 업데이트 • Jan 19
TGTX: Shares Should Rebound As Revenue Outlook Strengthens On Updated Guidance
Narrative Update Analysts have nudged their price target for TG Therapeutics higher to about $44.86, up from roughly $44.29. This reflects updated earnings models that incorporate slightly higher profit margin assumptions, a modestly adjusted discount rate and a small change to expected future P/E levels following recent Street research, including target increases from BofA, Goldman Sachs and JPMorgan.내러티브 업데이트 • Jan 05
TGTX: Higher JPMorgan Price View Will Likely Overstate Future Earnings Delivery
TG Therapeutics' analyst price target has moved higher, with a recent US$3 increase to US$49 as analysts refreshed their models after the latest earnings update. Analyst Commentary The latest move to a US$49 price target from JPMorgan signals that at least one major firm has refreshed its view following the recent earnings update, with a focus on updated assumptions in its valuation model.내러티브 업데이트 • Dec 22
TGTX: Higher Earnings Visibility Will Support A Re-Rating Over Time
Analysts have lifted their price target on TG Therapeutics shares, raising fair value by about $7 per share to $60, as updated post earnings models factor in a higher future P/E multiple despite slightly lower growth and margin assumptions. Analyst Commentary Following the latest earnings update, bullish analysts are increasingly highlighting TG Therapeutics as a beneficiary of improving fundamentals and greater earnings visibility, which they see as supporting a higher valuation range over the medium term.내러티브 업데이트 • Dec 08
TGTX: Shares Will Likely Rebound As Long Term Sales Milestone Approaches
Analysts have modestly raised their blended price target for TG Therapeutics, reflecting increased confidence in multi year Briumvi growth and updated post earnings models that point to a path toward more than $1 billion in annual sales. Analyst Commentary Recent Street updates reflect a predominantly constructive stance on TG Therapeutics, with upwardly revised price targets and reinforced positive ratings following the latest earnings update.내러티브 업데이트 • Nov 24
TGTX: Shares Will Likely Rebound Following Recent Buyback And Earnings Dip
Analysts have raised their price targets for TG Therapeutics, with recent updates reflecting increases of $3 to $49 and $2 to $55. This is based on confidence in ongoing sales growth and an improved margin outlook following the company's earnings report.내러티브 업데이트 • Nov 05
TGTX: Shares Will Likely See Renewed Momentum With Expanding U.S. Drug Adoption
Analysts have modestly increased their price target for TG Therapeutics, raising it from approximately $43.57 to $44.29. This adjustment is due to optimism about multi-year sales growth for Briumvi and updated post-earnings forecasts.분석 기사 • Oct 23
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...내러티브 업데이트 • Oct 22
Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets
Narrative Update on TG Therapeutics Analysts have raised their price target for TG Therapeutics by $2 to $55. They cite expectations for sustained multi-year sales growth, supported by strong prospects for Briumvi in the U.S. market.내러티브 업데이트 • Oct 08
A Subcutaneous Launch Will Unlock The Anti-CD20 MS Market
Analysts have raised their price target for TG Therapeutics from $40.50 to $43.57, citing expectations of sustained Briumvi sales growth and an improved revenue outlook. Analyst Commentary Recent Street research highlights a range of perspectives regarding TG Therapeutics, with particular focus on Briumvi's market performance and growth trajectory.분석 기사 • Sep 30
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Jul 29
Revenues Not Telling The Story For TG Therapeutics, Inc. (NASDAQ:TGTX)
You may think that with a price-to-sales (or "P/S") ratio of 13.6x TG Therapeutics, Inc. ( NASDAQ:TGTX ) is a stock to...Seeking Alpha • Mar 14
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Summary TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy. TG Therapeutics' strong cash position and ongoing Briumvi revenues are expected to fund operations and potential portfolio expansion, despite risks from trial data and international approvals. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Summary TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from subcutaneous Briumvi's trial. I expect the FY 2025 net sales guidance range to be at or slightly below the analyst consensus as the company sets the stage to beat and raise throughout the year. The company set expectations for a once every two-month dosing schedule for subcutaneous Briumvi, and I would consider quarterly dosing a clear win. Read the full article on Seeking Alpha
새로운 내러티브 • Sep 04
BRIUMVI's Breakthrough In MS Market Promises Robust Revenue Surge And Expanding Therapeutic Horizons
Strong sales of BRIUMVI and strategic expansions such as innovative versions aim to secure market dominance in treating relapsing multiple sclerosis.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$462m |
| Dec 31 2025 | US$26m | US$875k | US$447m |
| Sep 30 2025 | n/a | n/a | US$447m |
| Jun 30 2025 | n/a | n/a | US$60m |
| Mar 31 2025 | n/a | n/a | US$39m |
| Dec 31 2024 | US$19m | US$875k | US$23m |
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | US$96m |
| Mar 31 2024 | n/a | n/a | US$41m |
| Dec 31 2023 | US$18m | US$875k | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$224m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
보상 대 시장: Mike의 총 보수(USD25.57M)는 US 시장에서 비슷한 규모 기업의 평균(USD8.26M)보다 높습니다.
보상과 수익: Mike의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Mike Weiss (60 yo)
14.6yrs
재임 기간
US$25,571,250
보수
Mr. Michael S. Weiss, also known as Mike, Esq., J.D., serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Pres...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman | 14.6yrs | US$25.57m | 3.46% $ 269.3m | |
| CFO, Corporate Secretary & Treasurer | 14.6yrs | US$3.77m | 0.49% $ 37.9m | |
| Senior Vice President of Corporate Communications | no data | 데이터 없음 | 데이터 없음 | |
| Chief Commercialization Officer | 8.1yrs | 데이터 없음 | 데이터 없음 |
14.6yrs
평균 재임 기간
경험이 풍부한 관리: TGTX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 14.6 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman | 14.6yrs | US$25.57m | 3.46% $ 269.3m | |
| Lead Independent Director | 14.3yrs | US$943.02k | 0.13% $ 9.9m | |
| Independent Director | 11.6yrs | US$651.01k | 0.20% $ 15.4m | |
| Independent Director | 13.7yrs | US$646.76k | 0.16% $ 12.3m | |
| Independent Director | 6.3yrs | US$644.26k | 0.066% $ 5.2m | |
| Independent Director | 11.1yrs | US$646.76k | 0.14% $ 10.6m |
12.6yrs
평균 재임 기간
60.5yo
평균 나이
경험이 풍부한 이사회: TGTX의 이사회는 노련하고 경험이 풍부합니다(평균 재임 12.6 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/01 01:41 |
| 종가 | 2026/06/30 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
TG Therapeutics, Inc.는 17명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Alec Stranahan | BofA Global Research |
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |